GB Patent

GB1202148A — Pharmaceutical compositions

Assigned to Sankyo Co Ltd · Expires 1970-08-12 · 56y expired

What this patent protects

1,202,148. Antitussives. SANKYO CO. Ltd. 6 March, 1968. No. 10957/68. Heading A5B. Antitussive pharmaceutical compositions comprise 14-hydroxy-dihydro-6-beta-thebainol- 4-methyl ether as active ingredient and comprise a sterile solution syrup or suspension for oral administration…

USPTO Abstract

1,202,148. Antitussives. SANKYO CO. Ltd. 6 March, 1968. No. 10957/68. Heading A5B. Antitussive pharmaceutical compositions comprise 14-hydroxy-dihydro-6-beta-thebainol- 4-methyl ether as active ingredient and comprise a sterile solution syrup or suspension for oral administration, a pressurised composition containing a liquified propellant or the active ingredient in admixture with a solid pharmaceutical carrier or diluent. The compositions may be administered orally as tablets optionally coated, powders, capsules or granules and the sterile solutions optionally contain preservatives and antibacterial agents.

Drugs covered by this patent

Patent Metadata

Patent number
GB1202148A
Jurisdiction
GB
Classification
Expires
1970-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Sankyo Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.